Methods of treating and preventing melanoma with s-equol

Abstract

The present invention provides methods and compositions for treating or preventing melanoma with S-equol. The S-equol may be administered alone or in combination with one or more cytotoxic or immunotherapeutic compound or molecule.

1 . A method for treating or preventing melanoma, comprising administering a pharmaceutically effective amount of a formulation comprising S-equol to a subject in need thereof. 
     
     
         2 . The method of  claim 1 , wherein the formulation comprises 10-200 mg S-equol. 
     
     
         3 . The method of  claim 1 , wherein the formulation comprises 50-150 mg S-equol. 
     
     
         4 . The method of  claim 1 , wherein the formulation comprises about 50 mg S-equol. 
     
     
         5 . The method of  claim 1 , wherein the formulation comprises about 150 mg S-equol. 
     
     
         6 . The method of  claim 1 , wherein the formulation is administered orally, intravenously, intraperitoneally, or subcutaneously. 
     
     
         7 . The method of  claim 1 , wherein said subject is a human. 
     
     
         8 . The method of  claim 1 , wherein the S-equol is administered in combination with one or more other cancer treatments. 
     
     
         9 . The method of  claim 8 , wherein the S-equol is administered in combination with an immunotherapeutic agent. 
     
     
         10 . The method of  claim 9 , wherein the immunotherapeutic agent is an antibody. 
     
     
         11 . The method of  claim 10 , wherein the antibody is directed to programmed cell death protein 1 (PD-1). 
     
     
         12 . The method of  claim 11 , wherein the antibody is directed to programmed death ligand 1 (PDL-1). 
     
     
         13 . The method of  claim 11 , wherein the antibody is pembrolizumab. 
     
     
         14 . The method of  claim 12 , wherein the antibody is atezolizumab. 
     
     
         15 . The method of  claim 12 , wherein the antibody is avelumab. 
     
     
         16 . The method of  claim 1 , wherein the formulation is essentially free of genistein, daidzein, and/or IBSO03569. 
     
     
         17 . The method of  claim 1 , wherein genistein, daidzein, and/or IBSO03569 are not co-administered with S-equol. 
     
     
         18 . The method of  claim 1 , wherein the formulation is essentially free of R-equol. 
     
     
         19 . The method of  claim 1 , wherein the S-equol is produced chemically. 
     
     
         20 . The method of  claim 1 , wherein the formulation is administered once per day. 
     
     
         21 . The method of  claim 1 , wherein the formulation is administered twice per day. 
     
     
         22 . The method of  claim 1 , wherein the formulation is administered three times per day. 
     
     
         23 . The method of  claim 1 , wherein the formulation is administered four times per day.